TY  - GEN
AU  - Takashima,Naoki
AU  - Kimura,Tomoki
AU  - Watanabe,Naohiro
AU  - Umemura,Takumi
AU  - Katsuno,Shinya
AU  - Arakawa,Keiko
AU  - Fukatsu,Masahiro
AU  - Nakamura,Naoto
AU  - Nishiyama,Osamu
AU  - Kataoka,Kensuke
AU  - Kondoh,Yasuhiro
AU  - Taniguchi,Hiroyuki
TI  - Prognosis in patients with non-small cell lung cancer who received erlotinib treatment and subsequent dose reduction due to skin rash
SN  - 1423-0240
PY  - 2013///0605
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Comorbidity
KW  - Dose-Response Relationship, Drug
KW  - Drug Eruptions
KW  - epidemiology
KW  - Erlotinib Hydrochloride
KW  - Female
KW  - Humans
KW  - Japan
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Prevalence
KW  - Prognosis
KW  - Protein Kinase Inhibitors
KW  - therapeutic use
KW  - Quinazolines
KW  - Risk Assessment
KW  - Risk Factors
KW  - Survival Analysis
KW  - Survival Rate
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1159/000345039
ER  -